{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:37:54Z","timestamp":1793410674970,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.neuropharm.2023.109546","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T18:39:25Z","timestamp":1681583965000},"page":"109546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Preclinical evidence for the use of the atypical antipsychotic, brexpiprazole, for opioid use disorder"],"prefix":"10.1016","volume":"233","author":[{"given":"Julia E.R.","family":"Nickols","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-851X","authenticated-orcid":false,"given":"Serdar M.","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7881-8783","authenticated-orcid":false,"given":"Anna M.W.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109546_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2014.09.004","article-title":"The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice","volume":"742","author":"Almeida-Santos","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109546_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/npr2.12076","article-title":"Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5\u2010HT2A receptors in rats","volume":"39","author":"Amada","year":"2019","journal-title":"Neuropsychopharmacol Rep"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-006-0578-x","article-title":"The debate over dopamine's role in reward: the case for incentive salience","volume":"191","author":"Berridge","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/ejn.14580","article-title":"Divergent behavioral responses in protracted opioid withdrawal in male and female C57BL\/6J mice","volume":"51","author":"Bravo","year":"2020","journal-title":"Eur. J. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109546_bib5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.tips.2016.08.002","article-title":"Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation","volume":"37","author":"Cahill","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109546_bib6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/AJP.0b013e31816b2f43","article-title":"Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations","volume":"24","author":"Chu","year":"2008","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.neuropharm.2023.109546_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.808002","article-title":"Long-acting injectable antipsychotic treatment in schizophrenia and Co-occurring substance use disorders: a systematic review","volume":"12","author":"Coles","year":"2021","journal-title":"Front. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.neuropharm.2007.10.015","article-title":"Morphine-induced analgesic tolerance, locomotor sensitization and physical dependence do not require modification of mu opioid receptor, cdk5 and adenylate cyclase activity","volume":"54","author":"Contet","year":"2008","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109546_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2045125315614739","article-title":"Brexpiprazole: so far so good","volume":"6","author":"Das","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109546_bib10","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1046\/j.1460-9568.1998.00368.x","article-title":"Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization","volume":"10","author":"de Vries","year":"1998","journal-title":"Eur. J. Neurosci."},{"issue":"14","key":"10.1016\/j.neuropharm.2023.109546_bib11","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"di Chiara","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109546_bib12","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.neuropharm.2011.11.006","article-title":"Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF1 receptor antagonism","volume":"62","author":"Edwards","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109546_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40265-019-1052-5","article-title":"Brexpiprazole: a review in schizophrenia","volume":"79","author":"Frampton","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2023.109546_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000324065","article-title":"Introduction: addiction and brain reward and anti-reward pathways","volume":"30","author":"Gardner","year":"2011","journal-title":"Adv. Psychosom. Med."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2023.109546_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","article-title":"Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia","volume":"174","author":"Kane","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109546_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/npr2.12180","article-title":"Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole","volume":"41","author":"Kikuchi","year":"2021","journal-title":"Neuropsychopharmacol Rep"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109546_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","article-title":"Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement","volume":"87","author":"Koob","year":"2020","journal-title":"Biol. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109546_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2023.109546_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2007.09.016","article-title":"Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice","volume":"578","author":"Leite","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109546_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0149-7634(03)00073-3","article-title":"Effect of environmental stressors on opiate and psychostimulant reinforcement, reinstatement and discrimination in rats: a review","volume":"27","author":"Lu","year":"2003","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109546_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/srep39209","article-title":"Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: role of BDNF-TrkB signaling","volume":"6","author":"Ma","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.114.213819","article-title":"Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6642","key":"10.1016\/j.neuropharm.2023.109546_bib24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/41567","article-title":"Absence of opiate rewarding effects in mice lacking dopamine D2 receptors","volume":"388","author":"Maldonado","year":"1997","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.neuropharm.2023.109546_bib25","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2174\/1381612828666220623092853","article-title":"Atypical antipsychotic drugs in dual disorders: current evidence for clinical practice","volume":"28","author":"Martinotti","year":"2022","journal-title":"Curr. Pharmaceut. Des."},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109546_bib26","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41386-021-01118-y","article-title":"Anterior cingulate cortex is necessary for spontaneous opioid withdrawal and withdrawal-induced hyperalgesia in male mice","volume":"46","author":"McDevitt","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109546_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40263-016-0320-0","article-title":"Adjunctive brexpiprazole: a review in major depressive disorder","volume":"30","author":"McKeage","year":"2016","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0306-4522(02)00105-7","article-title":"Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal","volume":"112","author":"McNally","year":"2002","journal-title":"Neuroscience"},{"issue":"14","key":"10.1016\/j.neuropharm.2023.109546_bib29","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2174\/138161211796150783","article-title":"Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study","volume":"17","author":"Meini","year":"2011","journal-title":"Curr. Pharmaceut. Des."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109546_bib30","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00213-017-4543-7","article-title":"Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania","volume":"234","author":"Milienne-Petiot","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109546_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2015.02.025","article-title":"Dopamine receptor partial agonists and addiction","volume":"752","author":"Moreira","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"15","key":"10.1016\/j.neuropharm.2023.109546_bib32","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1523\/JNEUROSCI.5017-09.2010","article-title":"Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability","volume":"30","author":"Mozhui","year":"2010","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109546_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0166-4328(02)00297-8","article-title":"Persistence and drug-induced reinstatement of a morphine-induced conditioned place preference","volume":"136","author":"Mueller","year":"2002","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109546_bib34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.celrep.2019.09.034","article-title":"Allostatic changes in the cAMP system drive opioid-induced adaptation in striatal dopamine signaling","volume":"29","author":"Muntean","year":"2019","journal-title":"Cell Rep."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2023.109546_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejphar.2008.10.030","article-title":"Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer","volume":"600","author":"Narita","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109546_bib36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nn1578","article-title":"Is there a common molecular pathway for addiction?","volume":"8","author":"Nestler","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyv111","article-title":"Brexpiprazole alters monoaminergic systems following repeated administration: an in vivo electrophysiological study","volume":"19","author":"Oosterhof","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109546_bib38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bbr.2006.02.009","article-title":"Gender- and morphine dose-linked expression of spontaneous somatic opiate withdrawal in mice","volume":"170","author":"Papaleo","year":"2006","journal-title":"Behav. Brain Res."},{"issue":"24","key":"10.1016\/j.neuropharm.2023.109546_bib39","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1016\/j.neuron.2022.09.024","article-title":"Modulation of 5-HT release by dynorphin mediates social deficits during opioid withdrawal","volume":"110","author":"Pomrenze","year":"2022","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109546_bib40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4103\/1673-5374.250567","article-title":"The hypothalamic-spinal dopaminergic system: a target for pain modulation","volume":"14","author":"Puopolo","year":"2019","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109546_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1360-0443.2001.9611038.x","article-title":"Incentive-sensitization and addiction","volume":"96","author":"Robinson","year":"2001","journal-title":"Addiction"},{"issue":"1507","key":"10.1016\/j.neuropharm.2023.109546_bib42","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1098\/rstb.2008.0093","article-title":"The incentive sensitization theory of addiction: some current issues","volume":"363","author":"Robinson","year":"2008","journal-title":"Phil. Trans. Biol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109546_bib43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neuroscience.2016.06.029","article-title":"Opioid-induced hyperalgesia: cellular and molecular mechanisms","volume":"338","author":"Roeckel","year":"2016","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.neuropharm.2023.109546_bib44","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1523\/JNEUROSCI.22-08-03293.2002","article-title":"Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors","volume":"22","author":"Roug\u00e9-Pont","year":"2002","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109546_bib45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0306-4522(02)00257-9","article-title":"Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning","volume":"113","author":"Smith","year":"2002","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41386-018-0219-1","article-title":"State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia","volume":"44","author":"Sonnenschein","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109546_bib47","first-page":"1","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109546_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40801-020-00178-8","article-title":"Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and Co-occurring substance use disorders: a multicentre, observational study","volume":"7","author":"Szerman","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.neuropharm.2023.109546_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pbb.2015.03.011","article-title":"Prototypical anxiolytics do not reduce anxiety-like behavior in the open field in C57BL\/6J mice","volume":"133","author":"Thompson","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109546_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugalcdep.2016.06.024","article-title":"Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy","volume":"166","author":"Tsui","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/npp.2010.186","article-title":"A dopamine D1 receptor-dependent \u03b2-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice","volume":"36","author":"Urs","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109546_bib52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s002130050943","article-title":"Dopaminergic mechanisms mediating the long-term expression of locomotor sensitization following pre-exposure to morphine or amphetamine","volume":"143","author":"Vanderschuren","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109546_bib53","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6682275","article-title":"The distinct functions of dopaminergic receptors on pain modulation: a narrative review","volume":"2021","author":"Wang","year":"2021","journal-title":"Neural Plast."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109546_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.pbb.2009.01.014","article-title":"Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats","volume":"92","author":"xia Li","year":"2009","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823001363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823001363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:24:07Z","timestamp":1758439447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823001363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":54,"alternative-id":["S0028390823001363"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109546","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evidence for the use of the atypical antipsychotic, brexpiprazole, for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109546"}}